Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Alpelisib Granules and Tablets
NCT05195892Phase 1Completed
- Sponsor
- Novartis
- Start
- Feb 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of alpelisib in PIK3CA-related overgrowth spectrum (PROS) (6 arms), sponsored by Novartis. Primary endpoint: Maximum concentration of alpelisib at 96 hours. Started Feb 2022; status: completed.
02
Drugs
alpelisib
03
Conditions
PIK3CA-related overgrowth spectrum (PROS)
Beyond the preview
Go deeper on NCT05195892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05195892.